Trial Profile
Phase II study of a combination of CPT-11 and S-1 and Panitumumab in patients with KRAS wild-type metastatic colon cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Colon cancer
- Focus Therapeutic Use
- 03 Feb 2019 Status changed from recruiting to completed.
- 06 Apr 2011 New trial record